@article{MTMT:36983440,
	title = {Sustained complete remission with third-line nivolumab in advanced renal cell carcinoma: a case report},
	url = {https://m2.mtmt.hu/api/publication/36983440},
	author = {Küronya, Zsófia and Lénárt, Enikő and Soós, Edina and Géczi, Lajos and Bíró, Krisztina},
	doi = {10.1186/s13256-026-05886-3},
	journal-iso = {J MED CASE REP},
	journal = {JOURNAL OF MEDICAL CASE REPORTS},
	unique-id = {36983440},
	year = {2026},
	eissn = {1752-1947},
	orcid-numbers = {Küronya, Zsófia/0000-0001-8500-5924; Bíró, Krisztina/0000-0002-2070-0608}
}

@article{MTMT:37009547,
	title = {A metasztatikus kasztrációrezisztens prosztatarákos betegek abirateronkezelését befolyásoló komorbiditások metaanalízise},
	url = {https://m2.mtmt.hu/api/publication/37009547},
	author = {Budai, Barna and Fekete, Bertalan and Bíró, Krisztina and Lénárt, Enikő and Patócs, Attila Balázs and Géczi, Lajos},
	journal-iso = {MAGYAR ONKOLÓGIA},
	journal = {MAGYAR ONKOLÓGIA},
	volume = {70},
	unique-id = {37009547},
	issn = {0025-0244},
	year = {2026},
	eissn = {2060-0399},
	pages = {53-68},
	orcid-numbers = {Budai, Barna/0000-0001-9411-9202; Bíró, Krisztina/0000-0002-2070-0608; Patócs, Attila Balázs/0000-0001-7506-674X}
}

@article{MTMT:35630711,
	title = {Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer. Exploratory Analysis From the Phase 3 KEYNOTE-361 Study.},
	url = {https://m2.mtmt.hu/api/publication/35630711},
	author = {Powles, Thomas and Csőszi, Tibor and Loriot, Yohann and Matsubara, Nobuaki and Géczi, Lajos and Cheng, Susanna Y-S and Fradet, Yves and Alva, Ajjai and Oudard, Stéphane and Vulsteke, Christof and Morales-Barrera, Rafael and Fléchon, Aude and Gunduz, Seyda and Liu, Chih-Chin and Moreno, Blanca Homet and Bavle, Abhishek and Özgüroğlu, Mustafa},
	doi = {10.1016/j.clgc.2024.102261},
	journal-iso = {CLIN GENITOURIN CANC},
	journal = {CLINICAL GENITOURINARY CANCER},
	volume = {23},
	unique-id = {35630711},
	issn = {1558-7673},
	abstract = {KEYNOTE-361 evaluated first-line pembrolizumab with and without platinum-based chemotherapy versus chemotherapy alone in advanced or metastatic urothelial carcinoma. The primary end points of progression-free survival (PFS) or overall survival (OS) were not met. Exploratory analysis of efficacy by platinum agent (cisplatin or carboplatin) is reported.Eligible patients were randomly assigned 1:1:1 to receive pembrolizumab 200 mg intravenously every 3 weeks for ≤35 cycles with or without chemotherapy (gemcitabine with investigator's choice of either cisplatin or carboplatin) or chemotherapy alone. This exploratory subset analysis evaluated PFS and objective response rate (ORR) per RECIST v1.1 by blinded independent central review and OS for cisplatin- or carboplatin-based chemotherapy with versus without pembrolizumab for patients assigned to chemotherapy-containing arms of KEYNOTE-361.Of 1010 patients enrolled, 703 were assigned to receive a chemotherapy-containing regimen (n = 312 cisplatin based; n = 391 carboplatin based). Median follow-up was 31.3 months. For cisplatin-based arms, with versus without pembrolizumab, median OS was 20.1 versus 16.4 months (HR 0.88, 95% CI, 0.67-1.15) and median PFS was 8.5 versus 7.1 months (HR 0.67, 0.51-0.89). ORR was 64.1% versus 48.7%, respectively. For carboplatin-based arms, with versus without pembrolizumab, median OS was 15.5 versus 12.3 months (HR 0.84, 95% CI, 0.67-1.06) and median PFS was 8.0 versus 6.7 months (HR 0.86, 0.68-1.09). ORR was 47.2% versus 41.8%, respectively. Among patients in the cisplatin-based versus carboplatin-based chemotherapy alone arms, 55.8% versus 41.8% received a subsequent antiprogrammed cell death protein 1/ligand 1 therapy. The addition of pembrolizumab did not significantly increase the incidence of adverse events reported.Results suggest trends toward OS and PFS improvements with the addition of pembrolizumab to gemcitabine-platinum doublet over gemcitabine-platinum alone regardless of whether cisplatin or carboplatin was the chosen platinum agent. OS may have been influenced by active subsequent therapies.},
	keywords = {Urothelial carcinoma; PD-1/PD-L1; efficacy outcomes; platinum therapy; Immunnotherapy},
	year = {2025},
	eissn = {1938-0682},
	pages = {102261},
	orcid-numbers = {Géczi, Lajos/0000-0001-7432-2043}
}

@misc{MTMT:36128793,
	title = {Terápiás lehetőségek a legfrissebb ajánlások tükrében},
	url = {https://m2.mtmt.hu/api/publication/36128793},
	author = {Géczi, Lajos},
	unique-id = {36128793},
	year = {2025},
	orcid-numbers = {Géczi, Lajos/0000-0001-7432-2043}
}

@misc{MTMT:36128816,
	title = {Ritka lokalizációjú heredaganat áttétekkel szerzett tapasztalataink},
	url = {https://m2.mtmt.hu/api/publication/36128816},
	author = {Géczi, Lajos},
	unique-id = {36128816},
	year = {2025},
	orcid-numbers = {Géczi, Lajos/0000-0001-7432-2043}
}

@article{MTMT:36183013,
	title = {A Belügyminisztérium egészségügyi szakmai irányelve a prosztatarák komplex diagnosztikájáról és ellátásáról},
	url = {https://m2.mtmt.hu/api/publication/36183013},
	author = {Polgár, Csaba and Tenke, Péter and Kiss, András and Battyáni, István and Kincses, Zsigmond Tamás and Györke, Tamás and Molnár, Mária Judit and Zaletnyik, Zita and Hock, Márta and Géczi, Lajos and Küronya, Zsófia and Maráz, Anikó and Mangel, László and Ágoston, Péter Zoltán and Jorgo, Kliton and Nyirády, Péter and Bajory, Zoltán and Szepesváry, Zsolt and Melegh, Zsombor and Kuthi, Levente and Székely, Eszter and Borka, Katalin and Salamon, Ferenc and Gődény, Mária and Kalina, Ildikó and Korda, Dávid and Besenyi, Zsuzsanna and Patócs, Attila Balázs and Lacsán, Katalin Anna and Kapitány, Zsuzsanna and Friedrichné, Nagy Andrea},
	journal-iso = {EGÉSZSÉGÜGYI KÖZLÖNY},
	journal = {EGÉSZSÉGÜGYI KÖZLÖNY},
	volume = {75},
	unique-id = {36183013},
	issn = {2063-1146},
	year = {2025},
	eissn = {1419-029X},
	pages = {1006-1206},
	orcid-numbers = {Polgár, Csaba/0000-0001-7245-0762; Kincses, Zsigmond Tamás/0000-0002-1442-4475; Géczi, Lajos/0000-0001-7432-2043; Küronya, Zsófia/0000-0001-8500-5924; Ágoston, Péter Zoltán/0000-0003-0264-630X; Jorgo, Kliton/0000-0002-0325-6795; Melegh, Zsombor/0000-0001-7605-5719; Kuthi, Levente/0000-0001-9247-6679; Gődény, Mária/0000-0003-0020-3476; Patócs, Attila Balázs/0000-0001-7506-674X}
}

@article{MTMT:36245367,
	title = {Primer staging részeként végzett PSMA PET/CT hatása a klinikai döntésre},
	url = {https://m2.mtmt.hu/api/publication/36245367},
	author = {Küronya, Zsófia and Ágoston, Péter Zoltán and Jorgo, Kliton and Gesztesi, László and Kapuvári, Bence and Dombovári, P and Mavrogenis, Stelios and Géczi, Lajos and Lénárt, E and Dienes, T and Manninger, S and Szakáll, S and Martin, T and Bíró, Krisztina},
	journal-iso = {MAGYAR ONKOLÓGIA},
	journal = {MAGYAR ONKOLÓGIA},
	volume = {69},
	unique-id = {36245367},
	issn = {0025-0244},
	year = {2025},
	eissn = {2060-0399},
	pages = {203-207},
	orcid-numbers = {Küronya, Zsófia/0000-0001-8500-5924; Ágoston, Péter Zoltán/0000-0003-0264-630X; Jorgo, Kliton/0000-0002-0325-6795; Géczi, Lajos/0000-0001-7432-2043; Bíró, Krisztina/0000-0002-2070-0608}
}

@article{MTMT:36472513,
	title = {Aszinkron duplex HER-2-pozitív, előrehaladott emlődaganatos beteg eredményes kezelése tukatinib, transztuzumab, capecitabin kombinált kezeléssel},
	url = {https://m2.mtmt.hu/api/publication/36472513},
	author = {Géczi, Lajos},
	journal-iso = {ORVOSTOVÁBBKÉPZŐ SZLE},
	journal = {ORVOSTOVÁBBKÉPZŐ SZEMLE},
	volume = {32},
	unique-id = {36472513},
	issn = {1218-2583},
	year = {2025},
	pages = {63-66},
	orcid-numbers = {Géczi, Lajos/0000-0001-7432-2043}
}

@article{MTMT:36561333,
	title = {Az elsővonalbeli immunterápiával szerzett tapasztalatok az előrehaladott és áttétes vesedaganatos betegek kezelésésben},
	url = {https://m2.mtmt.hu/api/publication/36561333},
	author = {Nagyiványi, Krisztián András and Bíró, Krisztina and Budai, Barna and Dienes, Tamás and Gyergyay, Fruzsina and Kordáné Horváth, Orsolya and Lénárt, Enikő and Küronya, Zsófia and Pörneczy, Edit and Géczi, Lajos},
	journal-iso = {ONKOLÓGIA & HEMATOLÓGIA},
	journal = {ONKOLÓGIA & HEMATOLÓGIA: AZ ONCOLOGY FOLYÓIRAT MAGYAR NYELVŰ KIADÁSA},
	volume = {15},
	unique-id = {36561333},
	issn = {2559-8066},
	year = {2025},
	pages = {356-364},
	orcid-numbers = {Bíró, Krisztina/0000-0002-2070-0608; Budai, Barna/0000-0001-9411-9202; Kordáné Horváth, Orsolya/0000-0002-5456-7200; Küronya, Zsófia/0000-0001-8500-5924; Géczi, Lajos/0000-0001-7432-2043}
}

@article{MTMT:34827132,
	title = {First-line avelumab plus chemotherapy in patients with advanced solid tumors. results from the phase 1b/2 JAVELIN Chemotherapy Medley study.},
	url = {https://m2.mtmt.hu/api/publication/34827132},
	author = {Wheatley, Duncan A and Berardi, Rossana and Climent Duran, Miguel A and Tomiak, Anna and Greystoke, Alastair P and Joshua, Anthony M and Arkenau, Hendrik-Tobias and Géczi, Lajos and Garcia-Corbacho, Javier and Paz-Ares, Luis G and Hussain, Syed A and Petruželka, Lubos and Delmonte, Angelo and Chappey, Colombe and Masters, Joanna C and Michelon, Elisabete and Murphy, Danielle A and Mwewa, Sandrine and Cesari, Rossano and Doger de Speville, Bernard},
	doi = {10.1158/2767-9764.CRC-23-0459},
	journal-iso = {CANCER RES COMM},
	journal = {CANCER RESEARCH COMMUNICATIONS},
	volume = {4},
	unique-id = {34827132},
	abstract = {Chemotherapy can potentially enhance the activity of immune checkpoint inhibitors by promoting immune priming. The phase 1b/2 JAVELIN Chemotherapy Medley trial evaluated first-line avelumab + concurrent chemotherapy in patients with advanced urothelial carcinoma or nonsmall cell lung cancer (NSCLC).Avelumab 800 mg or 1200 mg was administered continuously every 3 weeks (Q3W) with standard doses of cisplatin + gemcitabine in patients with urothelial carcinoma, or carboplatin + pemetrexed in patients with nonsquamous NSCLC. Dual primary endpoints were dose-limiting toxicity (DLT; phase 1b) and confirmed objective response (phase 1b/2).In phase 1b, urothelial carcinoma and NSCLC cohorts received avelumab 800 mg (n=13 and n=6, respectively) or 1200 mg (n=6 each) + chemotherapy. In evaluable patients with urothelial carcinoma treated with avelumab 800 mg or 1200 mg + chemotherapy, DLT occurred in 1/12 (8.3%) and 1/6 (16.7%), respectively; no DLT occurred in the NSCLC cohort. In phase 2, 35 additional patients with urothelial carcinoma received avelumab 1200 mg + chemotherapy. Across all treated patients, safety profiles were similar irrespective of avelumab dose. Objective response rates (95% confidence internal) with avelumab 800 mg or 1200 mg + chemotherapy, respectively, across phase 1b/2, were 53.8% (25.1-80.8) and 39.0% (24.2-55.5) in urothelial carcinoma, and 50.0% (11.8-88.2) and 33.3% (4.3-77.7) in NSCLC.Preliminary efficacy and safety findings with avelumab + chemotherapy in urothelial carcinoma and NSCLC were consistent with previous studies of similar combination regimens. Conclusions about clinical activity are limited by small patient numbers.gov identifier, NCT03317496.},
	year = {2024},
	eissn = {2767-9764},
	pages = {1609-1619},
	orcid-numbers = {Géczi, Lajos/0000-0001-7432-2043}
}